Dose-dependent pharmacokinetics and first-pass effects of mirodenafil, a new erectogenic, in rats

✍ Scribed by Young H. Choi; Young S. Lee; Soo H. Bae; Tae K. Kim; Bong-Y. Lee; Myung G. Lee

• Publisher: John Wiley and Sons
• Year: 2009
• Tongue: English
• Weight: 162 KB
• Volume: 30
• Category: Article
• ISSN: 0142-2782
• DOI: 10.1002/bdd.669

✦ Synopsis

Abstract

The pharmacokinetics of mirodenafil and its two metabolites, SK3541 and SK3544, after intravenous (5, 10, 20 and 50 mg/kg) and oral (10, 20 and 50 mg/kg) administration of mirodenafil, and the first‐pass effect of mirodenafil after intravenous, oral, intraportal, intragastric and intraduodenal (20 mg/kg) administration of mirodenafil were evaluated in rats. The pharmacokinetics of mirodenafil and SK3541 were dose‐dependent after both intravenous and oral administration of mirodenafil due to the saturable hepatic metabolism of mirodenafil. After oral administration of mirodenafil, approximately 2.59% of the oral dose was not absorbed, the F value was approximately 29.4%, and the hepatic and gastrointestinal first‐pass effects of mirodenafil were approximately 21.4% and 54.3% of the oral dose, respectively. The low F value of mirodenafil in rats was mainly due to considerable hepatic and gastrointestinal first‐pass effects in rats. The equilibrium plasma‐to‐blood cell partition ratios of mirodenafil were independent of the initial blood mirodenafil concentrations of 1–10 µg/ml; the mean values were 1.08–1.21. The plasma binding values of mirodenafil to rat plasma was 87.8%. Copyright © 2009 John Wiley & Sons, Ltd.